Case Control Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. May 21, 2023; 29(19): 2979-2991
Published online May 21, 2023. doi: 10.3748/wjg.v29.i19.2979
Table 1 Baseline characteristics of the training, testing, and external validation sets, n (%)
Variables
Training cohort, n = 1163
Testing cohort, n = 291
Validation cohort, n = 197
P value
Age, yr57.60 ± 10.8357.56 ± 11.2359.72 ± 9.580.034
Male694 (59.67)163 (56.01)106 (53.81)0.206
BMI, kg/m222.79 ± 2.9222.89 ± 2.7522.61 ± 4.020.382
Neoadjuvant67 (5.76)19 (6.53)9 (4.57)0.659
Hypertension254 (21.84)66 (22.68)43 (21.83)0.952
Diabetes83 (7.14)26 (8.93)9 (4.57)0.185
Previous abdominal surgery141 (12.12)45 (15.46)22 (11.17)0.250
ASA < 0.001
    1178 (15.31)42 (14.43)55 (27.92)
    2893 (76.78)218 (74.91)89 (45.12)
    390 (7.74)30 (10.31)50 (25.38)
    42 (0.17)1 (0.34)3 (1.52)
Anastomotic height, cm4.82 ± 2.374.57 ± 2.144.77 ± 2.560.298
Specimen length, cm10.99 ± 3.0110.88 ± 3.1115.21 ± 4.49< 0.001
Diverting ileostomy315 (27.09)81 (27.84)35 (17.77)0.017
Tumor size, cm3.60 ± 1.293.53 ± 1.253.89 ± 1.350.546
Stage< 0.001
    1354 (30.44)91 (31.27)31 (15.74)
    2405 (34.82)94 (32.30)108 (54.82)
    3404 (34.74)106 (36.43)58 (29.44)
LARS0.800
    Minor/no731 (62.85)189 (64.95)124 (62.94)
    Major432 (37.15)102 (35.05)73 (37.06)